Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kempf

Showing results (401-410 of 415) with videos related to

Pageof 42
Sort By:
Journal of Medicinal Chemistry|June 17, 2016
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of ToxoplasmosisRama Subba Rao Vidadala, Kasey L Rivas, Kayode K Ojo, et al.
Journal of Medicinal Chemistry|February 20, 2009
Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazinesRolf Wagner, Daniel P Larson, David W A Beno, et al.
Journal of Medicinal Chemistry|June 9, 2006
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitorsZhonghua Pei, Xiaofeng Li, Kenton Longenecker, et al.
International Journal for Parasitology|September 14, 2017
Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosisMatthew A Hulverson, Ryan Choi, Samuel L M Arnold, et al.
Alimentary Pharmacology & Therapeutics|February 28, 2024
Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosisMarcus M Mücke, María Hernández-Tejero, Wenyi Gu, et al.
American Journal of Physiology. Cell Physiology|June 5, 2023
Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failureRobert Schierwagen, Wenyi Gu, Angela Brieger, et al.
International Journal for Parasitology|April 1, 2020
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learnedRyan Choi, Matthew A Hulverson, Wenlin Huang, et al.
Emerging Infectious Diseases|November 20, 2019
Canine Leishmaniasis Control in the Context of One HealthFilipe Dantas-Torres, Guadalupe Miró, Gad Baneth, et al.
Journal of Medicinal Chemistry|October 13, 2006
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetesDavid J Madar, Hana Kopecka, Daisy Pireh, et al.
Diagnostics (Basel, Switzerland)|August 7, 2021
Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging PathogensAlex van Belkum, Carina Almeida, Benjamin Bardiaux, et al.
Pageof 42

Showing results (401-410 of 415) with videos related to

Sort By:
Pageof 42
Journal of Medicinal Chemistry|June 17, 2016
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of ToxoplasmosisRama Subba Rao Vidadala, Kasey L Rivas, Kayode K Ojo, et al.
Journal of Medicinal Chemistry|February 20, 2009
Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazinesRolf Wagner, Daniel P Larson, David W A Beno, et al.
Journal of Medicinal Chemistry|June 9, 2006
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitorsZhonghua Pei, Xiaofeng Li, Kenton Longenecker, et al.
International Journal for Parasitology|September 14, 2017
Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosisMatthew A Hulverson, Ryan Choi, Samuel L M Arnold, et al.
Alimentary Pharmacology & Therapeutics|February 28, 2024
Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosisMarcus M Mücke, María Hernández-Tejero, Wenyi Gu, et al.
American Journal of Physiology. Cell Physiology|June 5, 2023
Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failureRobert Schierwagen, Wenyi Gu, Angela Brieger, et al.
International Journal for Parasitology|April 1, 2020
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learnedRyan Choi, Matthew A Hulverson, Wenlin Huang, et al.
Emerging Infectious Diseases|November 20, 2019
Canine Leishmaniasis Control in the Context of One HealthFilipe Dantas-Torres, Guadalupe Miró, Gad Baneth, et al.
Journal of Medicinal Chemistry|October 13, 2006
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetesDavid J Madar, Hana Kopecka, Daisy Pireh, et al.
Diagnostics (Basel, Switzerland)|August 7, 2021
Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging PathogensAlex van Belkum, Carina Almeida, Benjamin Bardiaux, et al.
Pageof 42